Sickle Cell Anemia Screening and Prevention in Northern Israel
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Since 1987, a screening for β Thalassemia in pregnant women is carried on in northern Israel, and from 1999 all the samples were tested also for Hgb S, Hgb C, Hgb D, Hgb O Arab and others.
In this study, the investigators intend to summarize the results of this preventive program aiming to detect couples at risk for having offspring with Thalassemia or SCA, the compliance regard to genetic counseling and prenatal diagnosis and the incidence of new affected babies born.
| Condition | Intervention |
|---|---|
|
Thalassemia Sickle Cell Anemia |
Other: Observational |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Summary of the Data From the Prevention Programme for Hemoglobinopathies in Northern Israel |
- Number of carriers detected [ Time Frame: End of study ] [ Designated as safety issue: No ]
- Couples referred for prenatal diagnosis [ Time Frame: End of study ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100000 |
| Study Start Date: | May 2008 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
A
Thalassemia Minor carriers
|
Other: Observational
Summary of data
|
|
B
Sickle cell carriers
|
Other: Observational
Summary of data
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
The program for prevention of hemoglobinopathies in Northern Israel, instituted since 1987, covered the northern part of Israel, including the Jezreel valley, the Nazareth area, the upper Galilee, the Hula valley and the northern part of the seashore region7. The overall population in this region is about a million inhabitants with about 50 % of Arab population, and a significant percentage of them from Bedouin origin, a population that at least partially is of African origin.
Inclusion Criteria: All pregnant women tested and their husband in those cases that the woman test revealed abnormal hemoglobin.
Exclusion Criteria: No exclusion criteria.
Contacts and Locations| Contact: Ariel Koren, MD | 972-4-6495576 ext 5576 | koren_a@clalit.org.il |
| Israel | |
| Pediatric Hematology Unit - Ha'Emek Medical Center | Recruiting |
| Afula, Israel, 18101 | |
| Contact: Ariel Koren, MD 972-4-6495576 ext 5576 koren_a@clalit.org.il | |
| Sub-Investigator: Carina Levin, MD | |
| Sub-Investigator: Luci Zalman, PhD | |
| Sub-Investigator: Ronit BGril Zamir, Msc | |
| Sub-Investigator: Stavit Shalev, MD | |
| Sub-Investigator: Haya Palmor | |
| Principal Investigator: | Ariel Koren, MD | Pediatric Hematology Unit - Ha'Emek Medical Center - Afula - 18101 - Israel |
More Information
No publications provided
| Responsible Party: | Dr Koren Ariel, Pediatric Dpt B and Pediatric Hematology Unit - Ha'Emek Medical Center - Afula - Israel |
| ClinicalTrials.gov Identifier: | NCT00735488 History of Changes |
| Other Study ID Numbers: | 0011-08-EMC |
| Study First Received: | August 14, 2008 |
| Last Updated: | September 3, 2009 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by HaEmek Medical Center, Israel:
|
Thalassemia Sickle cell anemia Carrier detection Prenatal Diagnosis Genetic counseling |
Additional relevant MeSH terms:
|
Anemia Anemia, Sickle Cell Thalassemia Hematologic Diseases |
Anemia, Hemolytic, Congenital Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn |
ClinicalTrials.gov processed this record on May 16, 2013